Shire just nabbed FDA panel backing for prucalopride, aiming to challenge Allergan and Synergy in the chronic constipation market.
Sanofi's beleaguered dengue vaccine is expected to win European approval in December following a committee's vote in favor of the shot this week.
As a big ESMO 2018 kicks off, here are the studies we're most excited to see.
China fines vaccine scandal-hit Changsheng $1.3 billion; Merck and Samsung bail on a Lantus biosim; Taiho grows VC fund to sixfold.
Novartis is raising its 2018 sales outlook, but canakinumab won’t help it hit the new target—at least not in the cardiovascular sales department.
The U.S. Senate has released a report on Insys that provides an insider’s view of a company leaning on physicians to help drive sales.
On Thursday, Merck’s Keytruda hit the scene with kidney cancer combination data that could snag it a new use months earlier than anticipated.
In a Humira patent deal with AbbVie, Fresenius Kabi will have to pay undisclosed royalties and can launch its biosim in Europe upon approval.
GlaxoSmithKline will lay off nearly 100 employees at a consumer products manufacturing plant in Memphis, Tennessee.
A week after Pfizer unveiled a reshuffled team that'll report to incoming CEO Albert Bourla, the drug giant says it plans to trim its workforce.
